I wonder in the neo-adjuvant setting whether there would be a case for combination of checkpoint inhibitor plus SCIB1 especially for patients with greater tumour load?
Who knows? Nevertheless, it would seem that by the time SCIB1 gets to trial in the adjuvant setting, the landscape will be different and the standard of care treatment for the control arm of the SCIB1 trial probably won't be interferon or Yervoy but more likely one of the PD-1's/L1's.
Still leaves the market wide open for Scancell in that arena,even in the neo pre-surgery application, but we win hands down because of zero toxicity. It would be interesting to know the result if the surgery was delayed by 6 months prior, if the resultant T cell Build up if given only SCIb1 would be greater with the cancer in place but still checked from growing by the release of the immune response, then surgery to remove the cancer, with further boosters to maintain that response.
Below is link to a very good summary of the current state of play of adjuvant therapies for melanoma. Interesting to note the move towards neo-adjuvant therapy and also the ongoing trials some of which are due to report this year.
2cvguy, for sure everybody has an opinion, fortunately on our traditional off topic Sunday a few of us had something to say and it is always good to share how we feel about Scancell, our stratagies in an honest way.
One aspect of this share is the reality of living with cancer, its complications and it is very hard to get over the deep psychological harm being diagnosed and given a short prognosis has on sufferers. I remember The Melanoma Kid with fondness. He didn"t make it as still… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.